Press Releases Year None2024202320222021202020192018 Mar 05, 2024 Akero Therapeutics Announces Pricing of Public Offering of Common Stock Mar 04, 2024 Akero Therapeutics Announces Proposed Public Offering of Common Stock Mar 04, 2024 Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study Feb 29, 2024 Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH Feb 29, 2024 Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Jan 03, 2024 Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 16 of 16
Year None2024202320222021202020192018 Mar 05, 2024 Akero Therapeutics Announces Pricing of Public Offering of Common Stock Mar 04, 2024 Akero Therapeutics Announces Proposed Public Offering of Common Stock Mar 04, 2024 Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study Feb 29, 2024 Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH Feb 29, 2024 Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Jan 03, 2024 Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 16 of 16
Mar 04, 2024 Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
Feb 29, 2024 Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
Feb 29, 2024 Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
